跳到正文
原文
Medical Xpress·· 10 天前精选AI 评分80

新MRI扫描技术‘颜色编码’治疗抵抗性癌症细胞,减少部分患者接受高强度治疗

New MRI scan 'color codes' treatment-resistant cancer cells, sparing some patients from aggressive treatment

AI 导读

伦敦癌症研究所与UCL和曼彻斯特大学合作开发的HYPOXiMAP技术,通过MRI显示肿瘤中的低氧区域,帮助临床医生识别可接受较低放疗剂量的患者,减少长期副作用。该技术有望改变放疗计划方式,实现个性化治疗。

推荐理由

介绍了新的MRI技术HYPOXiMAP,可帮助识别需要较低剂量放疗的患者,减少长期副作用。

正文 · 原文
mri
Credit: CC0 Public Domain

Scientists are developing a new MRI-based test that could spare thousands of cancer patients from aggressive radiotherapy treatment.

The pioneering imaging technology works by "color-coding" oxygen-starved cancerous tissue on scans and could be used to help clinicians identify which patients with HPV-positive throat cancer can receive lower doses of radiotherapy that provide the same treatment benefit while reducing long-term side effects.

The technique, known as HYPOXiMAP, is being developed by researchers at The Institute of Cancer Research, London, in collaboration with University College London and The University of Manchester.

Color-coding treatment-resistant cancer

The technique uses advanced MRI to reveal pockets of hypoxia—areas of low oxygen within tumors that are known to make cancer cells more resistant to radiotherapy.

HYPOXiMAP provides this information as a vivid, intuitive color map. Blue areas reveal hypoxic, treatment-resistant tissue, while yellow shows well-oxygenated regions that typically respond well to radiotherapy. Being able to provide this information in real time will one day allow smart radiotherapy systems that can automatically adjust themselves to provide gentler treatment whenever appropriate.

Reducing the long-term impact of radiotherapy

There are around 13,000 new cases of head and neck cancer in the U.K. every year. Rates of HPV-positive oropharyngeal (throat) cancer are increasing sharply, with a 47% rise in cases between 2013 and 2019.

Around 70% of patients are treated with radiotherapy. However, the standard high dose used frequently results in long-term side effects, such as swallowing difficulties, dry mouth, taste changes and persistent fatigue. More than half of patients experience significant long-term side effects.

Finding the patients who need less treatment

The biological importance of hypoxia in solid tumors has been recognized for decades, with links established as early as the 1950s. This has driven scientific efforts to explore whether some patients—particularly those whose tumors show very low levels of hypoxia—could safely receive reduced radiation doses.

Studies in the United States have shown that a highly specialized form of PET scanning can identify well-oxygenated tumors suitable for radiotherapy dose reduction. However, these scans are very costly and available only in a limited number of research centers in the U.K., making them unsuitable for widespread NHS use or large-scale trials.

Since MRI scanners are already standard equipment in hospitals across the NHS, HYPOXiMAP is a more accessible alternative.

The research team has shown that the MRI-based method can reliably distinguish oxygen-rich from oxygen-poor HPV-positive throat cancers and can also monitor changes in tumor hypoxia during radiotherapy—providing clinicians with real-time feedback on how treatment is progressing.

Advancing imaging into clinical use

A four-year program of work unites academic, clinical and industry partners to advance HYPOXiMAP imaging toward clinical use. Over the next phase of work, the team will refine the imaging process using artificial intelligence (AI) to improve the speed, accuracy and consistency of tumor oxygenation measurements.

To ensure the technology can be used in larger clinical trials, the program includes a prospective, multicenter study managed by the ICR's Clinical Trials and Statistics Unit (ICR-CTSU) to test how consistently HYPOXiMAP performs across different hospitals and MRI scanners.

These results, alongside findings from earlier work, will be used to evaluate strategies for adapting radiotherapy treatment based on HYPOXiMAP imaging, supporting future clinical trials and helping bring the technology into routine care.

'Protecting quality of life without sacrificing cure rates'

In the future, oxygen-enhanced imaging could also help identify patients who might benefit from immune checkpoint inhibitor drugs, which are known to be less effective in hypoxic tumors.

Professor James O'Connor, professor of quantitative biomedical imaging at The Institute of Cancer Research, London, and professor of radiology at The University of Manchester, said, "HYPOXiMAP represents the culmination of 15 years of work to turn MRI into a tool that can show us exactly where low-oxygen, treatment-resistant cancer cells are located. This technology has the potential to transform how we tailor radiotherapy for patients.

"For those with HPV-positive throat cancer and well-oxygenated tumors, this technique could help us safely reduce treatment intensity—protecting quality of life without sacrificing cure rates. This new funding allows us to take the final steps to bring this technology into clinical trials and, ultimately, into the hands of clinicians across the NHS."

Professor Gary Zhang, professor of computational imaging at University College London (UCL) and a co-director of UCL Hawkes Institute, said, "This technology pioneered by Professor O'Connor can make a real difference in the care of many cancer patients. This new funding allows us to harness recent advances in AI to help make this incredible technology even more accessible, so more patients can benefit."

Professor Kevin Harrington, head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research, London, said, "For decades, we have known that low oxygen levels inside tumors can influence how cancer responds to therapy, but clinicians have lacked a practical way to visualize this biology in everyday practice.

"By translating that understanding into a precise and accessible MRI technique, this technology has the potential fundamentally to change how radiotherapy is planned for people with HPV-positive throat cancer. It brings us closer to truly personalized treatment—ensuring patients receive the intensity of therapy they need, while avoiding unnecessary side effects."

Dr. Catherine Elliott, director of research at Cancer Research UK, said, "Scientists have been at the forefront of developments in radiotherapy for decades. Thanks to advances in research, people today are benefiting from radiotherapy which kills cancer cells effectively, while minimizing damage to healthy tissue nearby.

"The HYPOXiMAP project aims to map those oxygen-rich areas where tumors are most susceptible to beams of radiation. This method could lead us to a hyper-targeted approach to radiotherapy, which substantially reduces long-term side effects. Ultimately, research like this will move us toward a world where people live longer, better lives, free from the fear of cancer."

Key medical concepts

Hypoxia

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: New MRI scan 'color codes' treatment-resistant cancer cells, sparing some patients from aggressive treatment (2026, November 10) retrieved 10 November 2026 from https://medicalxpress.com/news/2026-11-mri-scan-codes-treatment-resistant.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com